By | June 26, 2015

glam logo simple

Glass-Laser Mulitplexed Biosensors

Differential cancer diagnosis takes place daily in clinical settings for a better monitoring of patient responses to existing treatments. However outcome of this diagnosis is today still poor. Moreover, current technology to measure biomarker levels is expensive and sophisticated. Most cancer biomarker analysis use blood or biological tissues as the main source of material. These biopsies must be analyzed in specialized laboratories incurring in some limitations: high cost; specialized personnel and equipment; large amounts of biological material; long outcome delivery time; time consuming processes.


Therefore it exist a real need and urgency to have new diagnostic devices that provide diagnosis, prognosis, and monitoring data faster and with exquisite ultra-sensitivity on time to take the appropriate decisions to improve personalized diagnosis and therapy. The aim of GLAM project is to provide an innovative device to fulfill these requirements using soluble biomarkers for personalized diagnosis and therapy monitoring. Specifically we will design and develop a new diagnostic tool to detect biomarkers from biofluids obtained in a noninvasive manner, specifically focusing to urine and to genitourinary cancers, to help oncologist to take better treatment decisions, approaching personalized medicine.


GLAM will develop an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost. GLAM capitalizes on the unprecedented sensitivity achieved using laser microring resonators to detect key biomarkers in tumor development and treatment. Point of Care of the device will be carried out by preclinical and clinical sample analysis of genitourinary cancer patients to warrant personalized medicine.


Importantly the GLAM unique technology will make the device also usable with other biofluids and might also be used to help physicians with other biomarker driven.

LEITAT’s role in the project:

  • WP1 Biomarkers, biological tools (mAbs) and biological samples:: WP Leader. LEITAT will identify and select the biomarkers of genitourinary oncologic diseases with the highest predictive power. It will also generate these recombinant protein biomarkers and use them to immunize, screen and produce and purify high affinity monoclonal antibodies against them. Leitat holds an extensive experience in the identification of new and key biomarkers and targets in the oncology area. Moreover, its experience and expertise in the generation of new mAb has led to the progression up to phase II clinical trials of one of the antibodies generated in the past for Merck-Serono, and to the inclusion of several diagnostic antibodies in the Millipore catalogue.
  • WP5 Clinical Validation: analysis and procedures: LEITAT will help RUMC with the validation of the prototype GLAM device using clinical samples and will also compare the main characteristics of the new diagnostic device with the conventional immunochemical detection method (ELISA). According to the experience mentioned in the previous paragraph, Leitat has been performing diagnostic ELISA tests during the past years for both basic research, preclinical research and also for clinical research.
  • WP6 Regulatory, Dissemination & Exploitation: Together with all partners, LEITAT will ensure coherent external communication of the project and its results towards relevant target groups. In addition, LEITAT will support all partners in networking activities and in questions concerning stakeholder and media relations throughout the project.
  • WP7 Management: LEITAT will co-ordinate GLAM in all aspects of project management, including administrative, legal and financial matters, to ensure a smooth project implementation. As leader of WP7 LEITAT will be responsible of project monitoring, progress management, and decision making. LEITAT will facilitate the project workflow in general, stimulate interaction between the different project management bodies, and assume the role of a liaison between the project consortium and the European Commission.

Number of Contract: H2020/634928


Coordinator: Leitat


Email LEITAT manager in charge: Raquel de Sousa




Starts: 1st of May2015


Duration:  48 months




LEITAT Technological Center Spain
IBEC Spain
WizSoft Israel
ICFO Spain
RUMC The Netherlands
OPTOCAP United Kingdom
OBELIS Belgium

Leave a Reply

Your email address will not be published.